A clinical stage company developing a novel treatment for CTCL, a type of skin cancer which afflicts 100,000 new patients annually. Our R&D is based on a combined effort of Professor Hinanit Koltai, head of medical cannabis research at the national lab in ARO, Israel together with Professor Emmilia Hodek, director of Dermatology, Rabin Medical Center, Israel. Our R&D pipeline includes 2 additional skin oncology indications and anxiety related indications. Head Office in Toronto, Canada R&D in Israel